ClinicalTrials.gg
Active, not recruitingNCT07584720Updated Jun 29, 2026

Study of Midomafetamine in Healthy Adults

A Phase 1 interventional study of Midomafetamine HCl in Healthy Volunteers, sponsored by Resilient Pharmaceuticals. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Resilient Pharmaceuticals · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This Phase 1 study is designed to evaluate the safety and tolerability of midomafetamine in healthy adult participants. The study will also assess how the drug is processed in the body and characterize its effects following administration at two dose levels, including evaluation of cardiac safety using electrocardiographic assessments.

This is a single-center, open-label study in which participants will be enrolled into one of two cohorts receiving either a therapeutic dose or a supratherapeutic dose of midomafetamine. Participants will receive study drug in a split dose administration (an initial dose followed by an additional dose 1.5 hours later) and will undergo clinical assessments, laboratory testing, electrocardiographic monitoring, and monitoring for adverse events.

Information collected from this study will be used to support the ongoing clinical development of midomafetamine.

Read the detailed description

This Phase 1 study is a dedicated safety investigation conducted in healthy adult participants to further characterize the safety and tolerability of midomafetamine under controlled dosing conditions. Participants will receive a split dose administration of midomafetamine (an initial dose of study drug followed by an additional dose 1.5 hours later) in sequential dose cohorts intended to achieve therapeutic and supratherapeutic systemic exposure.

Safety assessments include monitoring of adverse events, clinical laboratory tests, vital signs, and electrocardiographic measurements. Electrocardiographic data, including assessment of corrected QT interval, will be collected to support evaluation of cardiac safety in relation to exposure.

Because midomafetamine produces acute psychoactive effects during the dosing period, pharmacodynamic assessments-including subjective effects-will be collected to support interpretation of safety and tolerability findings. Pharmacokinetic assessments will also be performed to characterize systemic exposure.

This study is not designed to evaluate efficacy or treatment effectiveness for any disease or condition. Information collected from this study will be used to support the ongoing clinical development of midomafetamine.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Midomafetamine
  • Phase 1 Study
  • Healthy Volunteers
  • Safety
  • Pharmacokinetics
  • Pharmacodynamics
  • ECG
03

In context

Lead sponsor

Resilient Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult participants, 18 to 55 years of age
  • Medically healthy as determined by medical history, physical examination, clinical laboratory testing, vital signs, and
  • Able and willing to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular, neurological, or psychiatric disease
  • Current or recent substance use disorder, or positive drug or alcohol screen at screening
  • Prior exposure to midomafetamine exceeding a protocol-defined limit intended to minimize confounding of safety assessments (no more than 10% of participants may have lifetime prior exposure)
  • Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with interpretation of study results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Experimental

    Participants receive midomafetamine administered in sequential dose cohorts. One cohort receives a targeted therapeutic dose administered in a split manner, and a subsequent cohort receives a supratherapeutic dose administered in a split manner.

    Drug: Midomafetamine HCl

Interventions

  • Midomafetamine HCl is administered orally to study participants.

    Also known as: Midomafetamine

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Assessment of adverse events and serious adverse events following administration of midomafetamine.

    Time frame: From signing of informed consent through End of Study visit (Day 30 +/- 2 Days)

Secondary outcomes

  1. Change from baseline in corrected QT interval (QTc) (ms)

    Corrected QT interval (QTc) will be assessed using 12-lead ECG data and summarized as change from baseline at multiple postdose timepoints through 24 hours after dosing.

    Time frame: Baseline (predose Day 1) and up to 24 hours postdose (Day 2)

  2. Maximum plasma concentration (Cmax) of midomafetamine

    Plasma midomafetamine concentrations will be measured, and maximum plasma concentration (Cmax) will be derived from the concentration-time data.

    Time frame: Predose (Day 1) through 48 hours postdose (Day 3)

  3. Time to maximum plasma concentration (Tmax) of midomafetamine

    Plasma midomafetamine concentrations will be measured, and time to maximum plasma concentration (Tmax) will be derived from the concentration-time data.

    Time frame: Predose (Day 1) through 48 hours postdose (Day 3)

  4. Area under the plasma concentration-time curve (AUC0-24) of midomafetamine

    Plasma midomafetamine concentrations will be measured, and area under the concentration-time curve from time 0 to 24 hours (AUC0-24) will be derived from the concentration-time data.

    Time frame: Predose (Day 1) through 24 hours postdose (Day 2)

  5. Change from baseline in subjective effects Visual Analog Scale (VAS) scores

    Subjective effects will be assessed using Visual Analog Scale (VAS) instruments and summarized as change from baseline at multiple postdose timepoints through 24 hours after dosing.

    Time frame: Baseline (predose Day 1) and up to 24 hours postdose (Day 2)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data collected in this study will not be shared. Summary level results may be reported in publications and regulatory submissions, as applicable.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 13, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Jul 23, 2026
CompletionEst.
Feb 28, 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07584720
Collaborators
Dr. Vince Clinical Research
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Apr 23, 2026
Primary completion
Jul 23, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Jun 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion